AIIRA And Incident Diabetes Mellitus

The prevalence of type 2 diabetes worldwide continues to increase. In 2000 the number of patients around DM 171 million, while the year 2030 is expected to reach 366 million people. As already known DM had a very important effect on the health and quality of human life, therefore, efforts are made to reduce the incidence of DM is very important.

The results of various large clinical trials have shown that treatment with ACE inhibitors or AIIRA (Cancer groups) can prevent or slow the occurrence of DM, which is approximately 15-30% lower new-onset DM.

Research on losartan alone (LIFE: losartan Reduction Intervention For Endpoint) reduce the risk of new diabetes about 25%.

Although the exact mechanism is not known clearly, allegedly the renin-angiotensin system, aldosterone has an important role in glucose homeostasis.

Several mechanisms RAA system inhibitors in reducing the incidence of new diabetes, among others:

* Effect of protection against the cell? pancreas by inhibiting vasoconstriction and fibrotik effects of angiotensin II in the pancreas.
* Increased insulin sensitivity by increasing blood flow to skeletal muscle.
* Inhibits bad effects of angiotensin II on insulin signal pathways through protein kinase C signal in skeletal muscle and cardiovascular tissue (causing insulin resistance).
* Improving the transport of glucose by increasing the expression of muscle GLUT -4.
* Activation of PPARg system (regulate the metabolism of carbohydrates and fats).
* To facilitate the change from preadiposit be adiposit mature cells (known to inhibit angiotensin II preadiposit changes adiposit into mature cells, which would cause the accumulation of fat in other tissues other than mature adiposit, namely liver, muscle and pancreas so that it will lead to insulin resistance).

Source: Kalbefarma | 05-Jan-2007 | NRA Medical